Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
NCT00186225 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250
Last updated 2020-04-09
Summary
To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.
Conditions
- Blood Cancer
- Blood and Marrow Transplant (BMT)
Interventions
- PROCEDURE
-
ablative allogeneic hematopoietic cell transplantation
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Laura Johnston · Stanford University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 4 Weeks
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1989-11-30
- Primary Completion
- 2007-06-30
- Completion
- 2010-05-31
Countries
- United States
Study Locations
More Related Trials
-
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
NCT00317785 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
NCT00003196 ·Status: COMPLETED ·Phase: NA
-
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
NCT00912223 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
NCT01982682 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00054327 ·Status: COMPLETED ·Phase: PHASE2
-
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
NCT00049504 ·Status: COMPLETED ·Phase: PHASE2
-
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00006042 ·Status: COMPLETED ·Phase: PHASE1
-
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
NCT00005988 ·Status: COMPLETED ·Phase: PHASE1
-
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00075478 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
NCT01349101 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
NCT00544115 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00044954 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies
NCT01818479 ·Status: TERMINATED ·Phase: PHASE1
-
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
NCT01203722 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
NCT00533923 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
NCT00143559 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
NCT00005622 ·Status: COMPLETED ·Phase: PHASE2
-
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00186823 ·Status: COMPLETED ·Phase: PHASE3
-
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
NCT01532635 ·Status: TERMINATED ·Phase: PHASE2
-
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
NCT03032783 ·Status: COMPLETED ·Phase: PHASE2
-
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
NCT01087294 ·Status: COMPLETED ·Phase: PHASE1
-
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
NCT00611351 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
NCT00472329 ·Status: UNKNOWN ·Phase: PHASE2
-
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01871441 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879 ·Status: TERMINATED ·Phase: PHASE2